The hormone GLP-1, made in the intestine and rises after eating, can stimulate insulin release and prevent glucagon release, lowering blood sugar levels
Semaglutide may be a strong option for patients who respond well to GLP-1 therapy, need a more established treatment path or tolerate it better
Individuals with a history of pancreatitis or serious kidney problems should exercise caution, as this medication may increase the risk of pancreatitis
These changes lead to the accumulation of damaged proteins in myocytes, thereby reducing their ability to adapt to physiological stress and increasing the risk of heart disease in old age
Understanding Insurance Coverage and Out-of-Pocket Costs Insurance coverage for Mounjaro depends on your specific plan and whether your doctor can justify the prescription as medically necessary
Other diabetes medication classes offer alternatives if GLP-1 therapy proves unsuitable: SGLT2 inhibitors (such as dapagliflozin or empagliflozin) provide cardiovascular and renal benefits without affecting gastric emptying, though require adequate renal function and carry risks of genital infections and diabetic ketoacidosis DPP-4 inhibitors (such as sitagliptin) work on the incretin system but with less pronounced gastrointestinal effects note these should not be combined with GLP-1 receptor agonists Traditional agents including metformin, sulfonylureas, or insulin may be appropriate depending on individual circumstances Any medication change should be made in consultation with your diabetes specialist or GP, considering your overall glycaemic control, cardiovascular risk profile, and treatment goals, in line with NICE NG28 guidance
